MEDVi QUAD is a compounded sublingual ED liquid whose 2026 brand recipe names sildenafil, tadalafil, PT-141, and L-citrulline. Side-effect expectations should be built from those ingredients’ labeled or supplement-known profiles, not from a fake “12% of users” widget. Last verified August 2026.
What Side Effects Should You Expect?
Common PDE5-class effects include headache, flushing, indigestion, stuffy nose, and muscle or back aches. Serious labeled warnings for sildenafil and tadalafil include hypotension with nitrates. See also MEDVi Quad and nitrates and who should not take it, priapism, and sudden vision or hearing loss. Bremelanotide’s approved product label highlights nausea and blood-pressure changes. L-citrulline is usually discussed as GI upset at supplement doses, which may not match this liquid’s undisclosed milligrams.
| Ingredient class | Often discussed effects | Stop-and-call-a-clinician flags |
|---|---|---|
| Sildenafil / tadalafil | Headache, flushing, dyspepsia, congestion | Chest pain, faintness, vision/hearing change, erection over 4 hours |
| PT-141 / bremelanotide | Nausea, flushing, headache | Significant blood-pressure symptoms per clinician advice |
| L-citrulline | GI discomfort in supplement literature | Unknown in this combo; report unexpected symptoms |
Why Combining Four Actives Matters
Each ingredient can be discussed alone. Together, overlapping vasodilatory and nausea pathways can stack. That is why multi-drug compounded ED liquids deserve more caution than a single generic tablet, not less. Ranking pages that treat “4-in-1” as pure upside without stacking language are incomplete.
Older formula pages that still warn mainly about apomorphine nausea may be describing a recipe that brand materials replaced in mid-2026. Match counseling to the bottle you receive.
Who Should Not Take It?
People who take nitrates for chest pain, who have been told they cannot use PDE5 inhibitors, or who have unstable heart disease should not self-enroll from an ad. A clinician has to screen drug lists (including alpha blockers and some antifungals or HIV meds that interact with PDE5 drugs).
- Nitrate medicines, classic emergency-level interaction with PDE5 drugs.
- Unstable cardiovascular disease, needs in-person clinical judgment, not an ad funnel.
- Prior serious reaction to sildenafil, tadalafil, vardenafil, or bremelanotide.
- Anyone seeking an FDA-approved finished combination product, this is not that.
We do not place a signup button immediately after that contraindication list on purpose. If you need the review context first, use the flagship review. How-to-use notes: how to use.
Related injection-name searches are a different drug: Quad-Mix injection side effects.
What We Will Not Invent
- Exact incidence percentages for this finished combo (no public combo label).
- A milligram chart that is not on your pharmacy label.
- Personal-use testimonials claiming “zero side effects.”
Sources Checked for This Page
- FDA warning letter MEDVi, LLC dba MEDVi, 721455, 20 February 2026.
- FDA product labels for sildenafil, tadalafil, and bremelanotide (Vyleesi).
- Brand-facing MEDVi pages and 2026 secondary reporting on the QUAD formula and list prices.
Individual ingredients such as sildenafil and tadalafil are FDA-approved for other indications; the combined compounded formulation has not been evaluated by the FDA as a finished product, standard for all compounded medicines.